Exome Asset Management »

Lipocine shares owned by Exome Asset Management

Quarter-by-quarter ownership of Lipocine (LPCN) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Lipocine

Tip: Access up to 7 years of quarterly data

All positions including Lipocine held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lipocine by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $486k 61k 7.99

More positions owned by Exome Asset Management

Praxis Precision Medicines I Com New (PRAX)
Cogent Biosciences (COGT)
Enliven Therapeutics (ELVN)
Ionis Pharmaceuticals (IONS)
Spdr Series Trust State Street Spd Put Option (XBI)
Guardant Health (GH)
Cytokinetics Com New (CYTK)
Eli Lilly & Co. (LLY)
Alumis (ALMS)
Bridgebio Pharma (BBIO)
Vera Therapeutics Cl A (VERA)
Insmed Com Par $.01 (INSM)
Anthem (ELV)
Agios Pharmaceuticals (AGIO)
United Therapeutics Corporation (UTHR)

View all positions for Exome Asset Management

Top funds holding Lipocine

Ikarian Capital
Squadron Capital Management
Eversept Partners
Vanguard Group
Rosalind Advisors
Vanguard Capital Management
AIGH Capital Management
Stempoint Capital
Boothbay Fund Management
Seven Fleet Capital Management
Birchview Capital
BlackRock
Mink Brook Asset Management
Geode Capital Management
Exome Asset Management

View all funds holding Lipocine